PointState Capital’s Nektar Therapeutics NKTR Stock Holding History

PointState Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-41,554	Closed	-$66.2M	–	191
2018 Q1	$66.2M	Sell	41,554 -220,157	-84%	-$284M	0.72%	43
2017 Q4	$234M	Buy	261,711 +156,358	+148%	+$92.5M	2.28%	12
2017 Q3	$37.9M	Sell	105,353 -10,047	-9%	-$3.14M	0.32%	69
2017 Q2	$33.8M	Buy	115,400 +85,167	+282%	+$24.6M	0.37%	57
2017 Q1	$10.6M	Buy	+30,233	New	+$6.8M	0.11%	94
2016 Q4	–	Sell	-36,667	Closed	-$9.45M	–	150
2016 Q3	$9.45M	Buy	36,667 +23,334	+175%	+$6.01M	0.1%	89
2016 Q2	$2.85M	Buy	+13,333	New	+$2.98M	0.06%	82
2016 Q1	–	Sell	-6,667	Closed	-$1.69M	–	109
2015 Q4	$1.69M	Buy	+6,667	New	+$1.37M	0.04%	78
2015 Q2	–	Sell	-40,000	Closed	-$6.6M	–	170
2015 Q1	$6.6M	Sell	40,000 -26,667	-40%	-$5.48M	0.09%	90
2014 Q4	$15.5M	Buy	+66,667	New	+$14.2M	0.26%	68
2013 Q4	–	Sell	-38,333	Closed	-$6.01M	–	167
2013 Q3	$6.01M	Buy	+38,333	New	+$7.09M	0.1%	95

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PointState Capital's NKTR Position: Q2 2018 in Review

PointState Capital sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 41,554 shares — an estimated $66.2M sold.

PointState Capital first reported a position in NKTR in Q3 2013 and held it in 11 quarters. The position peaked at $234M in Q4 2017. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

PointState Capital reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
PointState Capital sold 41,554 Nektar Therapeutics shares in Q2 2018, an estimated $66.2M.
PointState Capital first reported a position in Nektar Therapeutics in Q3 2013 and held it in 11 quarters.
PointState Capital's Nektar Therapeutics position peaked at $234M in Q4 2017.
379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.